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Abstract
Transforming growth factor-β (TGFβ) is a key mediator of fibrogenesis.
TGFβ is overexpressed and activated in fibrotic diseases, regulates fibroblast
differentiation into myofibroblasts and induces extracellular matrix deposition.
Platelet-derived growth factor (PDGF) is also a regulator of fibrogenesis. Some
studies showed a link between TGFβ and PDGF in certain fibrotic diseases. TGFβ
induces PDGF receptor alpha expression in scleroderma fibroblasts. PDGF-C
and -D are the most recently discovered ligands and also play a role in fibrosis. In
this study, we report the first link between TGFβ and PDGF-D and -C ligands. In
normal fibroblasts, TGFβ down-regulated PDGF-D expression and up-regulated
PDGF-C expression at the mRNA and protein levels. This phenomenon is not
limited to TGFβ since other growth factors implicated in fibrosis, such as FGF,
EGF and PDGF-B, also regulated PDGF-D and PDGF-C expression. Among
different kinase inhibitors, only TGFβ receptor inhibitors and th...
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Abstract
Transforming growth factor-b (TGFb) is a key mediator of fibrogenesis. TGFb is overexpressed and activated in fibrotic
diseases, regulates fibroblast differentiation into myofibroblasts and induces extracellular matrix deposition. Platelet-derived
growth factor (PDGF) is also a regulator of fibrogenesis. Some studies showed a link between TGFb and PDGF in certain
fibrotic diseases. TGFb induces PDGF receptor alpha expression in scleroderma fibroblasts. PDGF-C and -D are the most
recently discovered ligands and also play a role in fibrosis. In this study, we report the first link between TGFb and PDGF-D
and -C ligands. In normal fibroblasts, TGFb down-regulated PDGF-D expression and up-regulated PDGF-C expression at the
mRNA and protein levels. This phenomenon is not limited to TGFb since other growth factors implicated in fibrosis, such as
FGF, EGF and PDGF-B, also regulated PDGF-D and PDGF-C expression. Among different kinase inhibitors, only TGFb receptor
inhibitors and the IkB kinase (IKK) inhibitor BMS-345541 blocked the effect of TGFb. However, activation of the classical NF-
kB pathway was not involved. Interestingly, in a model of lung fibrosis induced by either bleomycin or silica, PDGF-D was
down-regulated, which correlates with the production of TGFb and other fibrotic growth factors. In conclusion, the down-
regulation of PDGF-D by TGFb and other growth factors may serve as a negative feedback in the network of cytokines that
control fibrosis.
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Introduction
Transforming growth factor-b (TGFb) family members are
cytokines that regulate numerous physiological processes such as
embryonic development, cell differentiation, proliferation, migra-
tion and extracellular matrix production [1,2]. TGFb has also
been linked to several human pathologies including fibrosis and
carcinogenesis [3,4,5]. TGFb is a central mediator of several
fibrotic diseases like renal fibrosis or liver fibrosis [6,7]. Smad
proteins are the core components of the intracellular signaling
cascade of TGFb receptors. The Smad proteins transduce signals
from the cell surface directly to the nucleus where they regulate
gene transcription in cooperation with co-activators and/or co-
repressors. In addition to the Smad pathway, also known as the
conventional pathway, Smad-independent pathways can be
activated by TGFb, including TGFb-associated kinase 1 (TAK1)
[8], certain MAPKs such as extracellular signal-regulated kinase
(ERK) 1 and 2, Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase [8,9]. The PI3K-Akt-mTOR pathway has
also been reported to be activated by TGFb [10]. The importance
of these alternative pathways, NF-kB in particular, has been
debated. NF-kB activation by TGFb seems to be cell type
dependent [11,12].
Platelet-derived growth factors (PDGF) are also major players in
fibrosis including intestinal, cardiac and liver fibrosis [13,14,15].
PDGFs are potent mitogens for myofibroblasts while TGFb
stimulates collagen deposition by these cells [16,17]. PDGF family
members are composed of 4 ligands A, B, C and D binding to two
receptors, alpha and beta. PDGF-A and -B are well characterized
and their role in fibrotic diseases is well established [13,14,15].
PDGF-C and -D were discovered more recently and are also
implicated in fibrosis. PDGF-C is overexpressed and is a potent
inducer of fibrosis in the heart [18], lung [19], kidney [20],
pancreas [21] and liver [22]. Fewer studies have linked PDGF-D
to fibrotic diseases. PDGF-D is overexpressed in fibrosis of the
liver [23] and kidney [24]. By contrast, one study showed a
negative correlation of PDGF-D expression in a mice model of
bleomycin-induced lung fibrosis [19].
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Crosstalk between TGFb and PDGF has been reported in
several fibrotic conditions. In a model of hepatic fibrosis, one
report showed that TGFb mediated the mitogenic effect of PDGF-
BB, but not PDGF-AA, and this effect was due to the up-
regulation of PDGFRb mRNA and cell surface expression [25]. In
scleroderma, TGFb also enhances PDGF-A-stimulated growth by
increasing the expression of PDGFRa [26]. All together these are
the most relevant studies that reported a regulation of PDGFs by
TGFb in fibrotic disorders.
In the present study, we demonstrate that TGFb down-regulates
PDGF-D expression in normal fibroblasts.
Materials and Methods
Ethics Statement
This study was approved by the local ethical committee for
animal experiments (Comite´ d’Ethique pour l’Expe´rimentation
Animale, Permit number LA1230312). Experiments were carried
out in strict accordance with the Belgian and European
regulations. All surgery was performed after euthanasia by
intraperitoneal injection of 20 mg of sodium pentobarbital (Certa,
Braine l’Alleud, Belgium), and all efforts were made to minimize
suffering.
Reagents and antibodies
Sources were as follows: Recombinant human TGFb1, PDGF-
BB, EGF, FGF-4 and IL1b were purchased from Peprotech; p38
inhibitors SB202190 and SB203580 from Millipore; HDAC
inhibitor Trichostatin (TSA) was a kind gift from Pr. De Smet
(Universite´ catholique de Louvain, Belgium); ALK5 inhibitor
SB431542, IKK inhibitor BMS-345541 and MEK1/2 inhibitor
U0126 were from Calbiochem; PI3K inhibitor LY294002 from
Cayman chemical; JNK inhibitor SP600125 from Sigma, PDGF-
D antibody from Santa Cruz; PDGF-C monoclonal antibody was
a kind gift from Pr. U. Eriksson (Ludwig Institute for Cancer
Research & Karolinska Institute, Sweden) [27]. Actin antibody
was from Sigma; anti-mouse HRP from Santa Cruz.
Cell lines
MRC5 human lung fibroblasts (Sigma-Aldrich), AG01518 and
AG01523 human foreskin fibroblasts (both from Coriell Institute
for Medical Research, Camden, NJ) [28] were grown in Quantum
333 fibroblast growth medium (PAA laboratories, Pasching,
Austria). HEK293T (from ATCC) cells were grown in DMEM
supplemented with 10% fetal bovine serum (FBS), 50 U/ml
penicillin and 50 mg/ml streptomycin (Gibco, Life Technologies).
Gamma2A human fibrosarcoma cells (a kind gift from Prof Stefan
Constantinescu, de Duve Institute, Belgium) were grown as
described by Dusa et al. [29].
Lentivirus-mediated stable gene silencing
Short hairpin RNA (shRNA) used in this study were as follows:
(i) pLKO.1 scramble shRNA: CCTAAGGTTAAGTCGCCC-
TCG (Addgene, 1864), (ii) pGIPZ shsmad4 (1): AGCAGT-
GACTTTGTATAGAGAA (Open Biosystems, V2LHS_37199),
(iii) pGIPZ shsmad4 (2): CACTGCTAAATTCTATGTTAAA
(Open Biosystems, V2LH6_37196). Lentiviral plasmids expressing
the above shRNAs were transfected with the packaging plasmid
pCMV-dr8.2 dvpr and the envelope plasmid pCMV-VSV-G
(Addgene catalog numbers 8455 and 8454) into HEK293T cells
using FuGENE 6 (Roche Applied Science) as described [30].
Virus-containing supernatants were collected at 36 and 60 hours
after transfection and used to infect fibroblasts in the presence of
8 mg/ml of polybrene (Sigma). Then cells were incubated with
standard growth medium containing 2 mg/ml puromycin for 3
days prior to cell analysis.
Reverse transcriptase-PCR and quantitative PCR analysis
Subconfluent AG01523 or MRC5 fibroblasts were plated at
600000 cells/plate, starved for 24 hours in the presence of 0.05%
essentially fatty acid free BSA (Sigma) and treated for 30 minutes
in presence or absence of the following inhibitors: TGFb receptor
inhibitor (SB431542, 10 mM), MEK1/2 inhibitor (U0126,
10 mM), p38 inhibitors (SB203580 and SB202190, 10 mM), IKK
inhibitor (BMS-345541, 10 mM), PI3K inhibitor (LY294002,
20 mM), HDAC inhibitor (TSA, 300 nM) or vehicle (DMSO).
Cells were then incubated during 24 hours in the presence of
TGFb (4 ng/ml). Total RNA was extracted from cells using the
Qiagen RNeasy extraction kit according to the manufacturer’s
instructions. Complementary DNA synthesis from total RNA was
performed following the M-MLV reverse transcriptase (Invitrogen)
protocol. Real time quantitative PCR (q-PCR) was performed
using SYBR-green (ABgene kit) on an iCycler instrument (Bio-
Rad) as described [30]. The expression of the RPLP0 and b-Actin
genes was used to normalize q-PCR experiments. All q-PCR
primer sequences used in this study are provided in Table S1.
Protein extraction and Western blotting
Subconfluent MRC5 cells were plated at 200000 cells/well (six
well plates), starved for 24 hours in the presence of 0.05%
essentially fatty acid free BSA (Sigma) and treated with or without
TGFb (4 ng/ml) during 24 or 48 hours. Cells were washed with
phosphate-buffered saline (PBS) and then lysed as described [30].
Equal amounts of total protein extracts were analyzed by SDS-
PAGE, then transferred on a polyvinylidene difluoride membrane
(PVDF) and subjected to antibodies against PDGF-D (1 mg/ml,
Santa Cruz), PDGF-C (1 mg/ml, monoclonal antibody) or b-actin
(0.5 mg/ml, Sigma).
Luciferase assay
Gamma-2A cells were plated in 24-well plates and transfected
using Lipofectamine 2000 (Invitrogen) with 1 mg p1168-PDGF-D-
luc vector [31] or 1 mg of CAGA12 vector [32] as a control, 1 mg
pcDNA3 or pEF-BOS-Alk5 [33] and 1.5 mg pE1F-b-galactosidase
(pDRIVEchEF1-RU5, Invitrogen) [28]. Cells were incubated for
4 hours, washed with PBS, and then cultured in normal medium
for 24 hours. Cells were then treated with 10 mM of IKK inhibitor
(BMS-345541) 30 min prior to TGFb stimulation (4 ng/ml) for
24 hours. We then measured the luciferase and b-galactosidase
activities.
Enzyme-linked immunoabsorbent assays (ELISA)
An ELISA kit was obtained to measure concentrations of
PDGF-DD (R&D systems) in supernatants of MRC5 cells cultured
in the absence or presence of TGFb (4 ng/ml) for 24 h. The
detection limit of this assay was 1.67 pg/ml.
Lung Fibrosis induced with crystalline silica particles
NMRI mice were instilled either with 2.5 mg of silica per mouse
or with NaCl for control condition. Three mice were used for
control group and four for the silica-treated group. Mice were
sacrificed 60 or 120 days post instillation by intraperitoneal
injection of 20 mg of sodium pentobarbital (Certa, Braine l’Alleud,
Belgium) and total RNA was extracted from their lung samples
[34].
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Statistical analysis
Results were analyzed by Student’s t-test. Multiple comparisons
were carried out using analysis of variance (ANOVA test). A
significance threshold was set on p-values #0.05. All experiments
were performed in at least three independent replicates.
Results
PDGF-D and PDGF-C are regulated by TGFb at the mRNA
and protein levels
We analyzed the expression of PDGF-D and PDGF-C genes by
RT-qPCR in MRC5 lung fibroblasts treated or not with TGFb for
various periods of time. PDGF-D mRNA expression was
significantly down-regulated by TGFb, whereas PDGF-C mRNA
was up-regulated (Figure 1A). We also observed a similar
regulation of these genes by TGFb in AG01518 and AG01523
fibroblasts (data not shown). By reanalyzing a publicly available
time course experiment, in which A549 epithelial cells were
stimulated with TGFb during 72 hours (GEO, reference
GDS3710), we observed that, starting from 16 hours of TGFb
stimulation, PDGF-D and PDGF-C were strikingly regulated in an
opposite manner, as in MRC5 cells (Figure 1B). To investigate
whether these observations were specific to TGFb we treated the
MRC5 cells with a selective inhibitor of TGFb receptor activity
(SB431542, Figures 2A and 2D). As expected, the inhibitor
reversed the effects of TGFb on PDGF-C and PDGF-D expression
levels.
PDGF-C and PDGF-D regulation by TGFb was confirmed at
the protein level by western blotting (Figures 2B and 2E). We next
measured PDGF-DD secretion by ELISA, using antibodies that
recognize the active form of PDGF-DD, in which the CUB
domain was removed. TGFb-induced down-regulation of PDGF-
D mRNA expression had a significant effect on its secretion in the
culture medium (Figure 2C). This was reflected by the lower levels
of active PDGF-DD protein in the supernatant following exposure
of the cells to TGFb in the presence of serum. We did not see any
effect of TGFb in the absence of serum, most likely because it
provides plasmin, which cleaves latent PDGF-DD [35].
Role of Smad4 in the down-regulation of PDGF-D by
TGFb
To further investigate the mechanism behind PDGF-D down-
regulation by TGFb stimulation, we tested the involvement of the
Smad pathway. We infected MRC5 fibroblasts with two different
shRNAs against Smad4 and compared PDGF-C and -D mRNA
expression after 24 hours in TGFb-treated versus non-treated
cells. TGFb strongly decreased PDGF-D expression, and this
reduction was only marginally prevented by Smad4 knock-down
(p,0.05; Figure S1A). The shRNA did not affect PDGF-C
regulation by TGFb (Figure S1B). As a control, we investigated
Collagen1A1 (Col1A1) expression, a well-known target of the
TGFb-Smad pathway [36]. TGFb treatment induced Col1A1
mRNA expression, and this induction was partially decreased by
Smad4 shRNA (Figure S1C). This partial effect can be explained
by the fact that Smad4 expression was not completely abolished
(Figure S1D).
Role of Smad-independent pathways in PDGF-D gene
regulation by TGFb
We next tested whether TGFb regulates PDGF-D through a
Smad-independent pathway. We used specific pharmacological
inhibitors to inhibit the PI3K, MAPK and IKK pathways in the
presence or absence of TGFb. Figure 3A shows the effect of PI3K
(LY294002) and MEK1/2 (U0126) inhibitors, Figure 3B, the
effect of two p38 MAPK inhibitors (SB202190 and SB203580) and
Figure 3C, the effect of a JNK inhibitor (SP600125). None of these
inhibitors influenced PDGF-D expression. These results suggested
that neither the PI3K nor MAPK pathways mediated PDGF-D
regulation by TGFb. We next investigated the NF-kB pathway, by
treating fibroblasts with an inhibitor of IKK (BMS-345541). The
IKK inhibitor alone had no effect on basal PDGF-D expression,
but it abrogated the inhibition of PDGF-D expression observed in
the presence of TGFb (Figure 3D). Similar results were obtained
in AG01523 fibroblasts (data not shown). These data suggest that
TGFb regulates PDGF-D via IKK or another unknown BMS-
345541 target.
PDGF-D is regulated at the transcriptional level by TGFb
through IKK
We next evaluated whether TGFb affected the activity of the
PDGF-D gene promoter in luciferase-reporter assays. We used
gamma-2A fibrosarcoma cells because they are suitable for the
transfection of luciferase reporters and because TGFb down-
regulated PDGF-D mRNA in these cells, as in fibroblasts (data not
shown). Cells were transfected with a plasmid encoding luciferase
under the control of the PDGF-D promoter, and treated or not
with TGFb. The CAGA12 promoter was used as a control
promoter, to verify the responsiveness of transfected cells to added
TGFb (Figure 4A). We observed a significant reduction of PDGF-
D promoter activity in the presence of TGFb (Figure 4A). PDGF-
D promoter activity was also significantly down-regulated in cells
co-transfected with a constitutively activated mutant of the TGFb
receptor chain ALK5 (activin receptor-like kinase), in the presence
or absence of TGFb (Figure 4A). Moreover, IKK inhibition
partially reversed the inhibitory effect of TGFb on PDGF-D
promoter activity (Figure 4B), confirming the results shown in
Figure 3.
PDGF-D is down-regulated in a mouse model of lung
fibrosis
TGFb is implicated in several fibrotic diseases. To analyze the
expression of PDGF-D and PDGF-C genes in the context of a
fibrotic disease, we performed RT-qPCR on lungs collected from
NMRI mice that have received intra-tracheal instillations of silica.
Mice developed lung fibrosis upon silica instillation, and Rabolli et
al. showed that TGFb is highly expressed and released in fibrotic
lungs by comparison to saline controls in this model [34]. PDGF-
D and PDGF-C gene expression was analyzed 60 and 120 days
post instillation by RT-qPCR. PDGF-D expression was signifi-
cantly down-regulated in fibrotic lungs by comparison to controls
(Figure 5A). PDGF-C expression, however, was not different in
fibrotic lungs by comparison to controls (Figure 5B). Similar
results were obtained with another strain of mice (C57/Bl6)
instilled or not with silica (data not shown).
PDGF-D is down-regulated by other growth factors
involved in fibrosis
We next tested whether, in addition to TGFb, other growth
factors could also regulate PDGF-D and PDGF-C expression. In
our previous microarray analysis, we found that PDGF-D
expression was significantly down-regulated in fibroblasts 24 hours
after stimulation with PDGF-BB or FGF-2 (Figure S2). Using RT-
qPCR, we observed that FGF, EGF and PDGF-BB down-regulated
PDGF-D and up-regulated PDGF-C expression (Figures 6A and
6B). We also investigated whether inflammatory cytokines could
PDGF-D Is Down-Regulated by TGFb
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regulate PDGF-D expression. Interleukin-1b, alone or in combina-
tion with TGFb, did not regulate PDGF-D expression (Figure 6C).
Discussion
In this study we have shown that TGFb regulates PDGF-C and
-D ligand expression at both the mRNA and the protein level in
normal human fibroblasts. To our knowledge, this is the first study
showing that the expression of PDGF-C and -D ligands is
regulated by TGFb. Furthermore, a recent study reported that
Bone morphogenetic proteins (BMPs), which are members of the
of TGFb superfamily, are repressors of PDGF-A in ovarian
granulosa cells and tumors [37]. Here we showed that TGFb
induced PDGF-C in normal fibroblasts whereas PDGF-D was
significantly down-regulated at the transcriptional level. Consis-
tently, TGFb inhibited PDGF-D secretion by the cells.
Smad proteins mediate TGFb signaling. Down-regulation of
Smad4 weakly restored PDGF-D expression in the presence of
TGFb. These partial effects might be explained in part by the fact
that Smad4 expression was not completely abolished but Smad-
independent pathways are likely to play a role. Additional non-
canonical pathways are known to transduce TGFb signals, and
include ERK1/2, p38, JNK or PI3K pathways [10]. We showed
that neither the PI3K nor the MAPK pathways are responsible for
PDGF-D regulation by TGFb. Moreover, a study performed in
renal fibrosis identified two non-canonical TGFb pathways, Abl
and mTORC1, that play an important role in the development of
fibrosis [38]. Our experiments with imatinib (an Abl inhibitor) and
rapamycin (an mTOR inhibitor) did not support the hypothesis
that these pathways played a role in PDGF-D regulation by TGFb
(data not shown). BMS-3455541, an IKK inhibitor, rescued
PDGF-D expression to the basal level in the presence of TGFb
suggesting a regulation through IKK.
Whether TGFb activates NF-kB pathway is not fully under-
stood and appears to be cell context dependent. Gingery et al.
described a mechanism of NF-kB activation by TGFb through a
TAK1/MEK1/2/AKT pathway, which promotes osteoclast
survival in cooperation with Smad2/3 [39]. We showed that
TGFb failed to induce p65 phosphorylation on Ser 536 in contrast
to the anti-inflammatory cytokine IL-1b which strongly activated
Figure 1. PDGF-D and PDGF-C are late targets of TGFb. (A) MRC5 human fibroblasts were treated with TGFb (4 ng/ml) for 2 to 24 hours. PDGF-
D and PDGF-C mRNA expression was analyzed by RT-qPCR and normalized with the housekeeping gene RPLP0 (*, p,0.05; **, p,0.01). (B) Published
microarray data were also reanalyzed for PDGF-C and –D expression (GEO database, reference GDS3710). In this experiment, A549 cells were
stimulated by TGFb1 for the indicated periods of time. Each time point was investigated in triplicates (p,0.001, ANOVA).
doi:10.1371/journal.pone.0108656.g001
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p65 (data not shown) but did not regulate PDGF-D in MRC5
fibroblasts. This demonstrates that activation of the classical NF-
kB pathway alone does not regulate PDGF-D.
Moreover, an interesting study reported a non-canonical NF-kB
activation pathway through TAK1 and NIK by silica in Rat2
fibroblasts [40]. Taken together with our results, it is likely that
TGFb activates NF-kB in fibroblasts through a non-classical
pathway. Alternatively, IKK may also signal independently of NF-
kB downstream TGFb. Finally, we cannot rule out a non-specific
effect of the IKK inhibitor.
Gene down-regulation frequently involves histone deacetylases
(HDAC). Figure S3 showed that HDAC strongly down-regulated
PDGF-D expression. Indeed, trichostatin A (TSA), an inhibitor of
HDAC, induced PDGF-D expression. However, TGFb strongly
repressed PDGF-D expression even in the presence of HDAC
inhibitor, indicating that HDAC regulated PDGF-D indepen-
dently of TGFb. Little information is available regarding PDGF-D
promoter regulation. Some studies reported that PDGF-D is
induced by Ets-1 and Sp1 transcription factors [41]. Sp1 is in
general described as an activator rather than a repressor of
transcription but some studies reported that Sp1 could act as an
Figure 2. PDGF-D and PDGF-C regulation by TGFb at the mRNA and protein levels. (A) and (D), MRC5 human fibroblasts were pre-treated
with TGFb receptor inhibitor SB431542 (10 mM) 30 min before treatment with TGFb (4 ng/ml) for 24 h. The control condition was treated with DMSO
alone. PDGF-D and PDGF-C mRNA expression was measured by RT-qPCR and normalized with the housekeeping gene RPLP0. (B) and (E) MRC5 cells
were treated with TGFb (4 ng/ml) for the indicated period of time. PDGF-D and PDGF-C protein expression was analyzed by western blotting. Blots
were re-hybridized with an anti-b-actin antibody as control. (C) Active PDGF-DD levels were measured by ELISA in the culture supernatant of MRC5
cells treated or untreated with TGFb 4 ng/ml for 24 h. The average of 3 experiments is shown with S.E.M, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0108656.g002
PDGF-D Is Down-Regulated by TGFb
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e108656
inhibitor. Irvine et al. showed that TGFb inhibits LPL gene
transcription through modulation of the action of Sp1 and Sp3.
The authors reported that TGFb stimulation reduces Sp1 DNA
binding [42]. Another study suggested also a negative regulation of
the AT1 receptor by TGFb through Sp1.
Unpublished experiments obtained in the lab, demonstrated
that the presence of serum down-regulated PDGF-D expression
and that this effect was even stronger in the presence of saturating
amounts of TGFb, suggesting that other growth factors may
regulate PDGF-D and PDGF-C expression. We showed that EGF,
FGF and PDGF-BB alone or combined reduced significantly
PDGF-D expression and induced PDGF-C expression confirming
our observation with serum. Interestingly, all these growth factors
have been linked to fibrosis: PDGF-B in liver fibrosis [15], EGF in
heart and renal fibrosis [43,44] and FGF-4 in lung and renal
fibrosis [45,46]. These factors do not efficiently activate Smad or
Figure 3. PDGF-D is regulated in a non-conventional manner by TGFb. MRC5 cells were pre-treated with (A) the PI3K inhibitor LY294002
20 mM or the MAPK inhibitor U0126 10 mM, (B) with an inhibitor of p38 (SB202190 or SB203580, 10 mM), (C) with a JNK inhibitor SP600125, 20 mM and
(D) with the IKK inhibitor BMS-345541 10 mM or vehicle (DMSO) for 30 min, then treated or untreated with TGFb 4 ng/ml for 24 h. PDGF-D mRNA
expression was measured by RT-qPCR and normalized with RPLP0 expression. The average of 3 experiments is shown with S.E.M, ** p,0.005, *** p,
0.0005.
doi:10.1371/journal.pone.0108656.g003
PDGF-D Is Down-Regulated by TGFb
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IKK proteins, thus further experiments will be required to identify
the pathway responsible for this effect. Moreover, some studies
have reported that FGF represses gene expression via the ERK/
Sp1 pathway. Bonello et al. showed in smooth muscle cells that
FGF-2 represses PDGFRa expression in an ERK/Sp1 dependent
manner. Phosphorylation of Sp1 upon FGF-2 stimulation switches
Sp1 from an activator to a repressor of PDGFRa expression [47].
This pathway was also reported in another study in breast cancer
cells where the authors showed that FGF-2 down-regulates TSP50
expression via the ERK/Sp1 pathway [48]. All together these
studies suggest a mechanism of negative regulation via Sp1 upon
FGF-2 activation. Our preliminary results do not go in the same
Figure 4. TGFb represses PDGF-D at the transcriptional level through an IKK-dependent pathway. We used a 1.3 kb fragment of the
PDGF-D promoter cloned upstream of the luciferase reporter gene [31]. (A) Gamma-2A cells were co-transfected with the PDGF-D promoter construct
or the CAGA12 promoter construct (positive control), with either empty vector or constitutively activated Alk5 [33] and with a control b-galactosidase
reporter [28]. Cells were treated with TGFb 4 ng/ml or left untreated for 24 h. (B) Gamma-2A cells were co-transfected with PDGF-D promoter
construct and with b-galactosidase. They were treated with BMS-345541 (10 mM) for 30 min and then TGFb was added for 24 h. In all experiments,
luciferase and b-galactosidase activities were measured and the luciferase activity was normalized by dividing by the b-galactosidase activity. The
mean of three independent experiments is shown.
doi:10.1371/journal.pone.0108656.g004
Figure 5. PDGF-D and PDGF-C expression in lung fibrosis induced by silica. RNA samples were harvested from lungs of three control mice
and four silica-treated mice. (A) PDGF-D and (B) PDGF-C gene expression was measured by quantitative PCR and reported to the expression of actin.
ANOVA analysis revealed that the effect of treatment was highly significant (p-value: ,2.2e-16, data not shown).
doi:10.1371/journal.pone.0108656.g005
PDGF-D Is Down-Regulated by TGFb
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direction as these studies because U0126, an inhibitor of ERK1/2
pathway, did not have any effect on PDGF-D expression upon
FGF-4 stimulation (data not shown).
Our observations in cultured fibroblasts may be relevant in
pathophysiological conditions. Indeed, we showed in a mouse
model of silica-induced lung fibrosis, in which TGFb expression is
highly increased [34], that PDGF-D mRNA expression was down-
regulated whereas PDGF-C mRNA expression remained un-
changed. These results were confirmed in two different strains of
mice. Furthermore, Zhuo et al. have described in another mouse
model of lung fibrosis induced by bleomycin that PDGF-D
expression was decreased and PDGF-C expression was increased
[19]. Our results shed a light on the potential mechanism of
PDGF-D regulation in this model of lung fibrosis. However, it is
unclear which cytokine regulates PDGF-D in vivo.
In summary, we showed that TGFb down-regulated PDGF-D
and up-regulated PDGF-C expression. The regulation of PDGF-D
expression was sensitive to BMS-345541. We speculate that this
regulation may represent a negative feedback in the network of
fibrotic cytokines.
Supporting Information
Figure S1 Role of Smad4 in PDGF-D regulation by
TGFb.
(TIF)
Figure S2 PDGF-B and FGF-2 decrease PDGF-D expres-
sion.
(TIF)
Figure 6. Growth factors regulate PDGF-D and PDGF-C expression. MRC5 cells were treated with TGFb 4 ng/ml, EGF 50 ng/ml, FGF-4 10 ng/
ml (in the presence of heparin 10 mg/ml), PDGF-BB 20 ng/ml alone or all together for 24 h and PDGF-D (A) and PDGF-C (B) gene expression was
measured by RT-qPCR. (C) AG01523 fibroblasts were treated with TGFb 4 ng/ml, IL-1b 10 ng/ml or both for 24 h and PDGF-D gene expression was
measured by q-PCR. The average of 3 experiments is shown with S.E.M, * p,0.05, ** p,0.005, *** p,0.0005.
doi:10.1371/journal.pone.0108656.g006
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Figure S3 The HDAC inhibitor TSA regulates PDGF-D
expression.
(TIF)
Table S1 q-PCR primer sequences.
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